These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33740205)

  • 61. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
    Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
    Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.
    King TA; Morrow M
    Nat Rev Clin Oncol; 2015 Jun; 12(6):335-43. PubMed ID: 25850554
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
    Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
    J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Neoadjuvant systemic therapy in breast cancer].
    Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
    Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Drug development: neoadjuvant opportunities in breast cancer.
    Rastogi P; Geyer CE; Mamounas EP; DeMichele A
    Am Soc Clin Oncol Educ Book; 2013; ():73-9. PubMed ID: 23714461
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer.
    Brennan M; Gass P; Häberle L; Wang D; Hartmann A; Lux MP; Beckmann MW; Untch M; Fasching PA
    Breast Cancer Res Treat; 2018 Oct; 171(3):747-758. PubMed ID: 29951969
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.
    Huang EH; Strom EA; Perkins GH; Oh JL; Chen AM; Meric-Bernstam F; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):352-7. PubMed ID: 16887286
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Evaluation of neoadjuvant therapy in breast carcinoma].
    Winzer KJ
    Chirurg; 2000 Dec; 71(12):1458-65. PubMed ID: 11195064
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
    Criscitiello C; Azim HA; Agbor-tarh D; de Azambuja E; Piccart M; Baselga J; Eidtmann H; Di Cosimo S; Bradbury I; Rubio IT
    Ann Oncol; 2013 Aug; 24(8):1980-5. PubMed ID: 23567146
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods.
    Espinosa-Bravo M; Sao Avilés A; Esgueva A; Córdoba O; Rodriguez J; Cortadellas T; Mendoza C; Salvador R; Xercavins J; Rubio IT
    Eur J Surg Oncol; 2011 Dec; 37(12):1038-43. PubMed ID: 21940138
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer].
    Maráz R; Boross G; Svébis M; Gyánti R; Vizhányó R; Hajnal L; Markó L; Szucs M; Ambrózay E; Lorincz M
    Magy Seb; 2005 Aug; 58(4):225-32. PubMed ID: 16261868
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
    Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
    Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey.
    Clough KB; Acosta-Marín V; Nos C; Alran S; Rouanet P; Garbay JR; Giard S; Verhaeghe JL; Houvenaeghel G; Flipo B; Dauplat J; Dorangeon PH; Classe JM; Rouzier R; Bonnier P
    Ann Surg Oncol; 2015 Oct; 22(11):3504-11. PubMed ID: 25665949
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of neoadjuvant chemotherapy on wound complications after breast surgery.
    Decker MR; Greenblatt DY; Havlena J; Wilke LG; Greenberg CC; Neuman HB
    Surgery; 2012 Sep; 152(3):382-8. PubMed ID: 22739071
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
    Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
    J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Locoregional Treatment for Early-Stage Breast Cancer: Current Status and Future Perspectives.
    Lavasani S; Healy E; Kansal K
    Curr Oncol; 2023 Aug; 30(8):7520-7531. PubMed ID: 37623026
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Option of the surgical mode for breast cancer based on the effect of neoadjuvant chemotherapy].
    Fukutomi T
    Nihon Geka Gakkai Zasshi; 2002 Nov; 103(11):803-5. PubMed ID: 12478855
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intraoperative ultrasound in conservative surgery for non-palpable breast cancer after neoadjuvant chemotherapy.
    Ramos M; Díez JC; Ramos T; Ruano R; Sancho M; González-Orús JM
    Int J Surg; 2014; 12(6):572-7. PubMed ID: 24735893
    [TBL] [Abstract][Full Text] [Related]  

  • 79. How do surgeons approach breast cancer surgery in Turkey? A national survey.
    Emiroğlu M; Inal A; Sert İ; İlhan E; Peker K; Gulcelik MA; Gürçelik MA; Güngör H; Salimoğlu S; Can D; Ellidokuz H; Aydın C
    Breast Cancer; 2015 Jul; 22(4):421-6. PubMed ID: 26317143
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments.
    Esgueva A; Siso C; Espinosa-Bravo M; Sobrido C; Miranda I; Salazar JP; Rubio IT
    J Surg Oncol; 2021 Jan; 123(1):71-79. PubMed ID: 33002230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.